Meister Keith A. sold $145.6M of ILMN (indirect holdings)

Meister Keith A. sold 679,574 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $214.19 ($202.37–$220.13, $145.56M total) across 28 trades over 2026-08-19 to 2026-08-21.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 21, 2026, 11:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 12:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
high confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishHigh
01

Why it matters

The sizable divestiture by a director may trigger short‑term sell pressure and influence analyst sentiment.

02

Market read

Large insider sale provides fresh material for traders; likely short‑term downside bias.

03

What to watch

Potential tax planning or diversification motives not disclosed.

Relevance 8/10Novelty 9/10Timing: post‑market Aug 21

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Director Meister Keith A. sold $145.6M (679,574 shares) of Illumina in open‑market trades.

Expected impact

Short‑term downward pressure on ILMN price.

Evidence & confidence

Sale size exceeds $100M and represents a significant portion of holdings, likely signaling reduced confidence.

Market effects

May raise concerns for the genomics/diagnostics sector about insider confidence.

Limited to US biotech market; no broader regional effect.

Minimal global impact beyond Illumina investors.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Illumina, Inc.

    US‑listed genomics and diagnostics firm (NASDAQ: ILMN).

  • Meister Keith A.

    Director of Illumina.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.